Penumbra Gets FDA Clearance for Technology for Treating Strokes

Dow Jones

Jun 12

By Kelly Cloonan

Penumbra received clearance from the Food and Drug Administration for a technology aimed at addressing acute ischemic stroke.

The medical-technology company said Thursday the clearance is for its Thunderbolt product, which uses advanced computer-assisted vacuum thrombectomy technology to detect, fatigue and completely ingest blood clots.

The technology is designed to minimize catheter manipulation and allow for safe, complete blood clot capture in order to restore blood flow to the brain and give patients a better chance at recovery, the company said.

"Thunderbolt marks the beginning of a new era in stroke management, one that we believe will fundamentally change outcomes for patients," said Shruthi Narayan, president of Penumbra.

Thunderbolt will be prepackaged with one of Penumbra's catheters, the company said.

Strokes are the second leading cause of death worldwide. Stroke mortality worldwide is projected to increase by 50% between 2020 to 2050, the company said, citing a recent analysis.

Shares were rising 3.3% after the bell.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

June 11, 2026 16:55 ET (20:55 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2642234089"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642234089\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642234089?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 04:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642234089","market":"nz","top_or_hot":-1,"title":"Penumbra Gets FDA Clearance for Technology for Treating Strokes","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Penumbra received clearance from the Food and Drug Administration for a technology aimed at addressing acute ischemic stroke. \n</p>\n<p>\n  The medical-technology company said Thursday the clearance is for its Thunderbolt product, which uses advanced computer-assisted vacuum thrombectomy technology to detect, fatigue and completely ingest blood clots. \n</p>\n<p>\n  The technology is designed to minimize catheter manipulation and allow for safe, complete blood clot capture in order to restore blood flow to the brain and give patients a better chance at recovery, the company said. \n</p>\n<p>\n  \"Thunderbolt marks the beginning of a new era in stroke management, one that we believe will fundamentally change outcomes for patients,\" said Shruthi Narayan, president of Penumbra. \n</p>\n<p>\n  Thunderbolt will be prepackaged with one of Penumbra's catheters, the company said. \n</p>\n<p>\n  Strokes are the second leading cause of death worldwide. Stroke mortality worldwide is projected to increase by 50% between 2020 to 2050, the company said, citing a recent analysis. \n</p>\n<p>\n  Shares were rising 3.3% after the bell. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 11, 2026 16:55 ET (20:55 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Penumbra Gets FDA Clearance for Technology for Treating Strokes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPenumbra Gets FDA Clearance for Technology for Treating Strokes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-12 04:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Penumbra received clearance from the Food and Drug Administration for a technology aimed at addressing acute ischemic stroke. \n</p>\n<p>\n  The medical-technology company said Thursday the clearance is for its Thunderbolt product, which uses advanced computer-assisted vacuum thrombectomy technology to detect, fatigue and completely ingest blood clots. \n</p>\n<p>\n  The technology is designed to minimize catheter manipulation and allow for safe, complete blood clot capture in order to restore blood flow to the brain and give patients a better chance at recovery, the company said. \n</p>\n<p>\n  \"Thunderbolt marks the beginning of a new era in stroke management, one that we believe will fundamentally change outcomes for patients,\" said Shruthi Narayan, president of Penumbra. \n</p>\n<p>\n  Thunderbolt will be prepackaged with one of Penumbra's catheters, the company said. \n</p>\n<p>\n  Strokes are the second leading cause of death worldwide. Stroke mortality worldwide is projected to increase by 50% between 2020 to 2050, the company said, citing a recent analysis. \n</p>\n<p>\n  Shares were rising 3.3% after the bell. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 11, 2026 16:55 ET (20:55 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642234089","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642234089","pubTimestamp":1781211300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Penumbra received clearance from the Food and Drug Administration for a technology aimed at addressing acute ischemic stroke.The medical-technology company said Thursday the clearance is for its Thunderbolt product, which uses advanced computer-assisted vacuum thrombectomy technology to detect, fatigue and completely ingest blood clots.The technology is designed to minimize catheter manipulation and allow for safe, complete blood clot capture in order to restore blood flow to the brain and give patients a better chance at recovery, the company said.\"Thunderbolt marks the beginning of a new era in stroke management, one that we believe will fundamentally change outcomes for patients,\" said Shruthi Narayan, president of Penumbra.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","BK4082":"医疗保健设备","PEN":"Penumbra Inc","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓"},"translate_title":"Penumbra治疗中风技术获得FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN":1.5,"LABU":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Penumbra received clearance from the Food and Drug Administration for a technology aimed at addressing acute ischemic stroke. \n\n\n  The medical-technology company said Thursday the clearance is for its Thunderbolt product, which uses advanced computer-assisted vacuum thrombectomy technology to detect, fatigue and completely ingest blood clots. \n\n\n  The technology is designed to minimize catheter manipulation and allow for safe, complete blood clot capture in order to restore blood flow to the brain and give patients a better chance at recovery, the company said. \n\n\n  \"Thunderbolt marks the beginning of a new era in stroke management, one that we believe will fundamentally change outcomes for patients,\" said Shruthi Narayan, president of Penumbra. \n\n\n  Thunderbolt will be prepackaged with one of Penumbra's catheters, the company said. \n\n\n  Strokes are the second leading cause of death worldwide. Stroke mortality worldwide is projected to increase by 50% between 2020 to 2050, the company said, citing a recent analysis. \n\n\n  Shares were rising 3.3% after the bell. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 11, 2026 16:55 ET (20:55 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}